Head-to-head evidence
GZR101 vs insulin icodec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
GZR101
Developed by Gan & Lee Pharmaceuticals
NCT06199505 · Phase 2 · completed
The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07387003 (registry estimate)
insulin icodec · Awiqli
Marketed by Novo Nordisk
NCT04760626 · Phase 3 · completed
The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.
Next expected readout: October 2027 · NCT07747402 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · insulin icodec's landscape